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a  b  s  t  r  a  c  t
Acidosis  is an important  cause  of mortality  in  severe  falciparum  malaria.  Lactic  acid  is  a major  contribu-
tor  to  metabolic  acidosis,  but accounts  for only one-quarter  of  the  strong  anion  gap.  Other  unidentiﬁed
organic  acids  have  an  independent  strong  prognostic  signiﬁcance  for a fatal  outcome.  In  this  study,  a
simultaneous  bio-analytical  method  for qualitative  and quantitative  assessment  in plasma  and  urine  of
eight small  organic  acids  potentially  contributing  to acidosis  in  severe  malaria  was  developed  and  val-
idated.  High-throughput  strong  anion  exchange  solid-phase  extraction  in  a 96-well  plate  format  was
used  for  sample  preparation.  Hydrophilic  interaction  liquid  chromatography  (HILIC)  coupled  to nega-
tive  mass  spectroscopy  was  utilized  for separation  and  detection.  Eight  possible  small  organic  acids;
l-lactic  acid  (LA),  -hydroxybutyric  acid (aHBA),  -hydroxybutyric  acid  (bHBA),  p-hydroxyphenyllactic
acid  (pHPLA),  malonic  acid (MA),  methylmalonic  acid  (MMA),  ethylmalonic  acid  (EMA)  and -ketoglutaric
acid  (aKGA)  were  analyzed  simultaneously  using  a ZIC-HILIC  column  with  an  isocratic  elution  containing
acetonitrile  and ammonium  acetate  buffer.  This  method  was  validated  according  to  U.S.  Food  and  Drug
Administration  guidelines  with  additional  validation  procedures  for endogenous  substances.  Accuracy
for  all  eight  acids  ranged  from  93.1%  to  104.0%,  and  the  within-day  and  between-day  precisions  (i.e.
relative  standard  deviations)  were  lower  than  5.5%  at all tested  concentrations.  The calibration  ranges
were:  2.5–2500  g/mL  for LA, 0.125–125  g/mL  for aHBA,  7.5–375  g/mL  for bHBA,  0.1–100  g/mL for
pHPLA, 1–1000  g/mL  for MA,  0.25–250  g/mL  for  MMA,  0.25–100  g/mL  for EMA,  and  30–1500  g/mL
for aKGA.  Clinical  applicability  was  demonstrated  by  analyzing  plasma  and  urine  samples  from  ﬁve
patients  with  severe  falciparum  malaria;  ﬁve  acids  had  increased  concentrations  in plasma  (range
LA  =  177–1169  g/mL,  aHBA =  4.70–38.4  g/mL,  bHBA  = 7.70–38.0  g/mL,  pHPLA  =  0.900–4.30  g/mL
and  aKGA  = 30.2–32.0)  and  seven  in urine  samples  (range  LA = 11.2–513  g/mL,  aHBA  = 1.50–69.5  g/mL,
bHBA  =  8.10–111  g/mL,  pHPLA  =  4.30–27.7  g/mL, MMA  =  0.300–13.3  g/mL,  EMA  =  0.300–48.1  g/mL
and  aKGA  =  30.4–107  g/mL).  In  conclusion,  a novel  bioanalytical  method  was  developed  and  validated
which  allows  for  simultaneous  quantiﬁcation  of eight  small  organic  acids  in  plasma  and  urine.  This  new
method  may  be  a useful  tool  for the  assessment  of  acidosis  in patients  with  severe  malaria,  and  other
y  acid
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1. Introduction
Acidosis is an important prognostic marker in severe falcip-
arum malaria, and a direct cause of death [1]. Lactic acid is a
major contributor to metabolic acidosis in severe malaria. Accu-
mulation of lactic acid is caused by anaerobic glycolysis due to
Open access under CC BY-NC-ND license.obstructed microcirculatory ﬂow, which results from sequestra-
tion of parasitized red blood cells [2,3]. However, lactic acid alone
does not account for the total acid load in patients with severe
malaria, as other yet unidentiﬁed organic acids contribute to the
icense.
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trong anion gap [2]. The unidentiﬁed acids have strong progno-
tic signiﬁcance, independent from lactate concentrations [2,4,5].
 previous study [2] in adult patients with severe malaria showed
 mean plasma strong anion gap of 11.1 mEq/L, of which only
.9 mEq/L could be explained by the increased plasma lactic acid
oncentration.
A preliminary screening of plasma and urine from healthy
olunteers and patients with severe malaria, and comparison
f biochemical pathways implicated in parasite metabolism and
evere human febrile illness, identiﬁed eight small organic acids
or further investigation in this study. These were l-lactic acid
LA), -hydroxybutyric acid (aHBA), -hydroxybutyric acid (bHBA),
-hydroxyphenyllactic acid (pHPLA), malonic acid (MA), methyl-
alonic acid (MMA), ethylmalonic acid (EMA) and -ketoglutaric
cid (aKGA).
Methods have been developed and validated to quantify some of
hese acids in biological ﬂuids, but there are no published methods
or the simultaneous quantiﬁcation of all eight acids hypothe-
ized to play an important role in acidosis in severe malaria.
revious methods have used gas chromatography–mass spectrom-
try (GC–MS) [6,7] and liquid chromatography–mass spectrometry
LC–MS) with ion-exchange separation mode [8,9]. Lakso et al.
uantiﬁed methylmalonic acid in human plasma using hydrophilic
nteraction liquid chromatography (HILIC) separation and MS
etection in single-stage negative electrospray ionization (ESI)
ode [10].
Solid-phase extraction (SPE) is commonly preferred to
ther conventional techniques (e.g. protein precipitation and
iquid–liquid extraction) since it provides cleaner extracts suitable
or separation coupled to MS  detection. Furthermore, the 96-well
PE format facilitates high-throughput processing for future rou-
ine analysis work. For separation and detection, HILIC has shown
ood retention and resolution of small polar acids [11] and the high
ontent of organic solvent in the mobile phase can enhance the
fﬁciency of the electrospray ionization (ESI) and thus the analyt-
cal sensitivity. Ion trap mass spectrometry has limited sensitivity
or quantiﬁcation of targeted acids. However, because of the high
ull-scan sensitivity and its ability to perform MSn, this was  chosen
s the most appropriate tool for the qualitative and quantitative
creening of the eight small organic acids thought to play a role in
evere malaria. Furthermore, this approach can be readily extended
or screening clinical samples to explore other potentially relevant
cids.
The objective of this study was to develop and validate a novel
C–MS method for simultaneous and accurate qualitative and
uantitative assessment of candidate acids in human plasma and
rine hypothesized to be important contributors to severe malaria
isease. This method could prove an important clinical tool for
tudying the pathogenesis of acidosis in malaria and other con-
itions complicated by acidosis.
. Experimental
.1. Chemicals and materials
l-Lactic acid (LA), -hydroxybutyric acid (aHBA), -
ydroxybutyric acid (bHBA), p-hydroxyphenyllactic acid (pHPLA),
alonic acid (MA), methylmalonic acid (MMA), ethylmalonic
cid (EMA), and -ketoglutaric acid (aKGA) were obtained from
igma–Aldrich (St. Louis MO,  USA). Stable isotope-labeled internal
tandards (SIL-IS) were obtained for all eight acids: l-lactic-
,3,3-d3 acid (LA-D3) from Sigma–Aldrich; -hydroxybutyric
cid-d4 (bHBA-D4) and ethyl-d5-malonic acid (EMA-D5) from
edical Isotopes (Pelham NH, USA); [ring-U-13C6]-2-hydroxy-3-
4-hydroxyphenyl)propanoic acid (pHPLA-13C6) from ALSACHIMtogr. B 941 (2013) 116– 122 117
(Illkirch-Graffenstaden, France); and malonic acid (MA-13C2),
methyl-d3-malonic acid (MMA-D3), and -ketoglutaric acid
disodium salt (1,2,3,4-13C4) from Cambridge Isotope Laboratories,
USA). Structures of analytes are shown in Fig. 1. Acetonitrile (HPLC
and MS  grade), water (HPLC and MS  grade) and methanol (HPLC
grade) were obtained from J.T. Baker (Phillipsburg NJ, USA). Formic
acid (HPLC grade) was from BDH Industries (Mumbai, India) and
ammonia solution (HPLC grade) was from Merck (Darmstadt,
Germany). Acetic acid (MS  grade) and ammonium acetate (MS
grade) were obtained from Sigma–Aldrich.
2.2. Instrumentation for liquid chromatography–mass
spectrometry
The chromatography was  performed on a Hitachi LaChrom®
Elite system consisting of a binary LC pump, a vacuum
degasser, a temperature-controlled autosampler set at 20 ◦C, and a
temperature-controlled column compartment set at 30 ◦C (Hitachi
High Technologies America, Pleasanton CA, USA). Data acquisition
and quantiﬁcation were performed using QuantAnalysis® version
1.7 (Bruker Daltonics, Bremen, Germany). The compounds were
separated on a ZIC®-HILIC column (250 mm × 2.1 mm)  protected
by a ZIC®-HILIC guard column (5 m,  20 mm × 2.1 mm)  (SeQuant,
Umea, Sweden) under isocratic conditions using a mobile phase
containing 100 mM acetonitrile/ammonium acetate (80:20, v/v),
pH 4.7, at a ﬂow rate of 0.5 mL/min within 13 min. The column was
then washed with 25 mM acetonitrile/ammonium acetate (50:50,
v/v), pH 4.7, at a ﬂow rate of 0.4 mL/min for 7 min. Before each
new injection, the LC system was  re-equilibrated for 1 min  with
the starting conditions (total run time 21 min).
An Esquire 4000 ion trap mass spectrometer (Bruker Daltonics,
Bremen, Germany), with electrospray ionization source (ESI) inter-
face operated in the negative ion mode, was used for detection.
The MS  conditions were optimized for all eight acid standards by
infusing 10 g/mL standard solutions in mobile phase at 10 L/min
using an infusion pump (Harvard Apparatus, Holliston MA,  USA)
connected directly to the mass spectrometer. Dry temperature of
desolvation was maintained at 365 ◦C, the capillary voltage was  set
at 3000 V, the dry gas was set to 8 L/min, and the nebulizer gas was
set to 40 psi. Quantiﬁcation was performed by extracting the target
mass (m/z) from the total ion chromatogram (TIC), with the follow-
ing target masses (m/z): 89.1 for LA; 92 for LA-D3; 103 for aHBA,
bHBA and MA;  107 for bHBA-D4; 105 for MA-13C2; 180.9 for pHPLA;
186.9 for pHPLA-13C6; 117 for MMA;  119.9 for MMA-D3; 131 for
EMA; 136 for EMA-D5; 144.9 for aKGA; and 148.9 for aKGA-13C4.
2.3. Preparation of calibration standards, internal standards and
quality controls
2.3.1. Calibration standards
All eight organic acids in this study were endogenous com-
pounds present in blank plasma and urine from healthy volunteers.
Calibration curves were therefore prepared in water, as analyte-
free surrogate matrix. The analytical response differences between
plasma/urine and water were evaluated by a recovery assess-
ment (see also Section 2.5). Stock solutions of all eight standards
were diluted in water to prepare working solutions. Finally,
combined working solutions of all eight acids were prepared
to build the six-point calibration curve (6 non-zero samples).
The ranges were 2.5–2500 g/mL for LA; 0.125–125 g/mL for
aHBA; 7.5–375 g/mL for bHBA; 0.1–100 g/mL for pHPLA;
1–1000 g/mL for MA;  0.25–250 g/mL for MMA;  0.25–100 g/mL
for EMA; and 30–1500 g/mL for aKGA. The calibration also
included a blank sample (blank without internal standard) and a
zero sample (blank with internal standard). The Limit of detection
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mFig. 1. Chemical structures of the eight potential organic acids thought to
LOD) and Lower limit of quantiﬁcation (LLOQ) were chosen as the
owest concentrations that could be distinguished reliably from the
ackground noise (i.e. signal-to-noise >3 for LOD and >10 for LLOQ)
12]. Calibration solutions were prepared, aliquoted and stored at
80 ◦C until analysis.
.3.2. Internal standards
The stable isotopically labeled internal standard (SIL-IS) stock
olutions were prepared in water. Since aHBA and bHBA presented
he same target mass (m/z), close retention times, and similar
hemical properties they shared the same SIL-IS (bHBA-D4). A com-
ined working solution of all 7 SIL-IS; LA-D3 (500 g/mL), bHBA-D4
25 g/mL), pHPLA-13C6 (10 g/mL), MA-13C2 (100 g/mL), MMA-
3 (50 g/mL), EMA-D5 (20 g/mL), and aKGA-13C4 (300 g/mL)
as prepared, aliquoted and stored at −80 ◦C until analysis.
.3.3. Quality controls (QC)
Three QC samples containing low, middle and high concentra-
ions of the eight acids were prepared in water at the following
oncentrations: 7.5, 1252 and 2252 g/mL for LA; 0.375, 62.6 and
13 g/mL for aHBA; 22.5, 188 and 338 g/mL for bHBA; 0.3, 50
nd 90 g/mL for pHPLA; 3, 501 and 901 g/mL for MA;  0.75, 125
nd 225 g/mL for MMA;  0.75, 50.1 and 90.1 g/mL for EMA; and
0, 751 and 1351 g/mL for aKGA. All QC solutions were prepared,
liquoted and stored at −80 ◦C until analysis.
.4. Sample collection
For plasma samples; whole blood was collected from study par-
icipants via a cannula inserted into a peripheral vein, into lithium
eparin tubes and placed on ice for immediate transit to the hos-
ital laboratory. Upon arrival, specimens were spun for 7 min  at
100 × g in a centrifuge refrigerated to 4 ◦C. Urine was collected
rom participants as a fresh specimen with a mid-stream urine
pecimen, into a tube with no additives. Plasma and urine were
ecanted into 2 mL  cryovials, and stored in liquid nitrogen or a
80 ◦C freezer. Transportation of all plasma and urine specimens
as undertaken in a liquid nitrogen dry shipper or (for periods
f under 36 h) on dry ice. All samples were taken with the fully
nformed written consent of either the patient or attendant rela-
ive, and were part of prospective clinical investigations in severe
alaria which were approved by the Ethical and Scientiﬁc Com-
ittee of the Centre for Tropical Diseases.a role in the pathophysiology of the metabolic acidosis in severe malaria.
2.5. Sample preparation
One hundred microliter of combined internal standard solution
was added to 100 L of sample (plasma or urine) in a 96-well plate
with an Eppendorf (Hamburg, Germany) stream multi-stepper.
An additional 800 L ammonium acetate buffer (pH 8.0; 2.5 mM)
was added with a 12-channel pipette, and the 96-well plate was
gently mixed (600 rpm) on an Eppendorf MixMateTM (Hamburg,
Germany) for about 10 min. The 96-well plate was  centrifuged
at 1100 × g for 10 min, and 1 mL  was  loaded into a conditioned
ISOLUTE PE-AX 96-well SPE plate (Biotage, Uppsala, Sweden). All
steps in the solid-phase extraction (SPE) procedure were con-
ducted using a 12-channel pipette, as follows. Conditioning; 1 mL
methanol was added to each SPE well, and a vacuum of 3–5 mmHg
was applied until all wells were empty (this step was performed
two times). Formic acid/methanol (15:85, v/v) conditioning/elution
solution was  added to each SPE well (vacuum of 3–5 mmHg) to
remove unwanted SPE impurities. Ammonium acetate buffer (pH
8.0; 2.5 mM)  was added to each well, and a vacuum of 3–5 mmHg
was applied until all wells were empty. Loading; 1 mL  of sample was
loaded into the 96-well and a vacuum of 1–1.5 mmHg  was applied
for 2 min. The vacuum was  increased by 0.5 mmHg every 2 min  until
all samples had passed through the wells. Washing; 1 mL  of water
followed by 1 mL  of methanol was  added to each well (vacuum of
3–5 mmHg). Full vacuum was applied for about 10 min, after which
the column tips were dried with tissue paper. Elution; a glass 96-
well 1 mL  collection plate was inserted into the vacuum manifold,
and 950 L conditioning/elution solvent (formic acid/methanol
(15:85, v/v)) was  added to each well. A vacuum of 0.5–1 mmHg  was
applied for 2 min  and increased by 0.5–1 mmHg every 2 min  until
all elution solvent had passed through the plate. The eluates were
evaporated to dryness in a TurboVap (Caliper, Massachusetts, USA)
using nitrogen gas at 40 ◦C until dryness (approximate 2 h). Recon-
stitution; 200 L mobile phase (100 mM acetonitrile/ammonium
acetate (80:20, v/v), pH 4.7) were added using a multistepper auto
pipette, and mixed on a MixMateTM at 800 rpm for approximately
10 min. Finally, 5 L of the reconstituted extracts were injected into
the LC–MS system.
2.6. ValidationThe US FDA guidelines for bioanlytical method validation [12]
does not contain any direct recommendation for the methods quan-
tifying endogenous compounds in biological ﬂuids. The validation
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as therefore performed according to available FDA guidance crite-
ia [12] with additional experiments for endogenous compounds
ased on published methods [13–15]. The calibration curve was
repared in water to avoid the potential bias resulting from endoge-
ous compounds occurring naturally at different concentrations
n all sources of blank biological ﬂuids. Additional experiments
ere performed to determine the differences in recoveries between
lasma/urine and water (see Section 3.2.2) [14,15]. Furthermore,
IL-IS were used to compensate for any variations during sample
rocessing and to compensate for the matrix differences between
amples and calibration curves.
Selectivity was evaluated by analysis of blank plasma and
rine samples from 6 healthy subjects and also in samples spiked
t LLOQ. Linearity, accuracy and precision were evaluated using
alibration curves in water on four separate occasions. All cali-
ration curves were constructed using the analytical responses
chromatographic peak area ratio between the investigated ana-
yte and the SIL-IS) using a linear regression model with 1/x2
eighting. Precision and accuracy at the lower and upper limits
f quantiﬁcation (at LLOQ and ULOQ) were evaluated by analyz-
ng three replicates. The carry-over of all eight acids and their 7
IL-IS were evaluated by injecting blank mobile phase immedi-
tely after the injection of a standard with ULOQ concentration.
ver-curve dilution was evaluated at three occasions, at a con-
entration two times greater than the ULOQ and then diluted ﬁve
imes with HPLC water prior analysis. The analytical responses of
ll eight acids in plasma/urine and water matrices were assessed
o ensure that the calibration curve built in water could be used
o quantify clinical plasma and urine samples. The slope coef-
cient (˛) of 3-point QC curves for all eight acids spiked in
lasma/urine from 6 different healthy sources were compared
ith their respective curves spiked in water solution; recovery
actor (RF) = ˛spiked plasma/urine/˛water. The back-calculated concen-
rations (C) of QC samples in pooled plasma/urine, with and without
F correction were used to calculate the sum of the absolute
alues of relative residuals to evaluate the two methodologies (rel-
tive residual = 100 × (Cspiked plasma/urine − Cnominal)/Cnominal)). The
rocess efﬁciency, recovery and matrix effects were determined
y comparing the area (A) of analytes in 6 individual sources
f healthy blank plasma/urine. Due to the potential presence of
ndogenous concentrations in the blank matrices, the individual
reas of the blank samples were subtracted from all sample values.
ach parameter was calculated according to the following formu-
as: process efﬁciency (%) = 100 × (Aspiked − Ablank)/Aneat, recovery
%) = 100 × (Aspiked − Ablank)/(Apost-spiked − Ablank) and matrix effect
%) = 100 × [(Apost-spiked − Ablank)/Aneat − 1]. A qualitative estimation
f the matrix effect was also performed through post-column infu-
ion experiments (infusion of all eight acids) with direct injection
f extracted blank plasma and urine samples.
Precision and accuracy of the QC samples were evaluated by
nalyzing ﬁve replicates at three different occasions. Intra-assay,
nter-assay, and total precisions were calculated at the 3 QC levels
sing analysis of variance (ANOVA) in GraphPad PRISM® version
.03 (GraphPad software Inc, California, USA).
The stability of all eight acids in pooled plasma/urine were eval-
ated at low and high QC levels by three replicates stored under
ifferent conditions and durations: three freeze-thaw cycles, ambi-
nt temperature and 4 ◦C for 48 h. Bench-top stability at ambient
emperature before SPE, and stability (in the autosampler at 20 ◦C)
ere evaluated for 4 h and 36 h, respectively.. Results and discussion
The objective of this study was to develop and validate a simul-
aneous and accurate bioanalytical method for the qualitative andtogr. B 941 (2013) 116– 122 119
quantitative assessment of eight organic acids in human biologi-
cal samples (plasma/urine), which might contribute signiﬁcantly
to acidosis in patients with severe malaria.
3.1. Method development
3.1.1. Instrumentation for liquid chromatography–mass
spectrometry
The electrospray ionization source (ESI) interface was oper-
ated in the negative ion mode to generate, focus and transport
the target ions to the ion-trap mass analyzer. This technique offers
atmospheric pressure ionization at a low temperature and there-
fore an efﬁcient ionization of polar compounds. The ESI conditions
were optimized (i.e. nebulizer pressure, drying gas ﬂow, drying gas
temperature and capillary voltage) for an efﬁcient production of
a ﬁne aerosol. The ion trap MS  parameters (i.e. octopole, lens and
trap drive) were optimized to generate and accumulate the ions
to achieve maximum responses of the target ions with the best
mass accuracy and resolution. All MS  conditions were optimized
for each individual compound and implemented in the combined
method for all eight acid standards. Even though quantifying eight
identiﬁed acids, the full mass scan of the ion trap combined with
the sample preparation for polar acids allow for identifying other
potentially important unknown acids.
All eight organic acids were soluble in water with pKa values
ranging from approximately 2.22 to 4.41 [16]. Earlier meth-
ods for small polar compounds employed GC–MS. However,
GC–techniques require samples to be volatile and have thermal
stability, and some samples must be derivatized prior to analysis
[6,17,18]. Ion-exchange chromatography requires mobile phases
that usually contain high levels of aqueous solvents which could
reduce the efﬁciency of the electrospray ionization (ESI) and thus
the analytical sensitivity [8,9].
Because of the polar properties of target analytes, a HILIC
method was  evaluated. HILIC can efﬁciently retain and separate
small polar compounds, which are not retained in conventional
reversed-phase LC [11]. HILIC also requires a high organic content in
the mobile phase which potentially increases the desolvation efﬁ-
ciency and enhances the MS  sensitivity. In HILIC, the recommended
ionic strength for the mobile phases is commonly between 5 and
20 mM but a 100 mM  buffer provided a signiﬁcant improvement in
peak shapes (data not shown). The wash step before subsequent
sample injection was  crucial to avoid endogenous interferences
from plasma and urine. This greatly improved the reproducibility of
the method and enabled high throughput analysis without degra-
dation of the chromatographic performance or rise in the column
back-pressure over an extended period of time.
3.1.2. Sample preparation
The ion-exchange SPE offered cleaner extracts which lead to
minimal ion suppression/enhancement for the compounds inves-
tigated [19] compared to conventional techniques such as protein
precipitation. Smaller volumes are also used with SPE and the
technique can be automated using a liquid handler. The SPE opti-
mization focused on minimizing the content of formic acid in the
elution since that resulted in the highest and most stable recover-
ies with appropriate evaporation time (optimal ratio was  15% (v/v)
formic acid in methanol).
3.2. Method validation
3.2.1. Selectivity
The chromatograms of all eight acids in blank plasma and urine
from healthy volunteers did not show any signals from interference
in samples (e.g. concomitant medication), they showed only the
endogenous analyte peaks) (i.e. peaks that are found naturally in
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Table 1
Method speciﬁcation and calibration range of eight organic acids compared with the concentrations found in plasma and urine samples from severe malaria patients and
healthy  subjects (from preliminary analysis).
Acids Molecular
weight (Da)
m/z  tR (min) LOD (g/mL) LLOQ (g/mL) Method
calibration
range (g/mL)
Concentration
range in
plasma
Concentration
range in urine
Severe malaria
patients (n = 5)
(g/mL)
Healthy
subjects (n = 5)
(g/mL)
Severe malaria
patients (n = 5)
(g/mL)
Healthy
subjects (n = 5)
(g/mL)
LA 90.1 89.1 4.30 0.750 2.50 2.50–2500 177–1169 77.0–113 11.2–513 19.4–30.9
aHBA  104.1 103.0 3.10 0.0375 0.125 0.125–125 4.70–38.4 1.50–3.20 1.50–69.5 2.40–18.8
bHBA  104.1 103.0 3.80 2.25 7.50 7.50–375 7.70–38.0 6.60–9.40 8.10–111 8.10–17.0
pHPLA 182.2 180.9 3.10 0.0300 0.100 0.100–100 0.90–4.30 0.100–0.400 4.30–27.7 0.600–28.2
MA  104.1 103.0 5.70 0.300 1.00 1.00–1000 <LOD <LOD <LOD <LOD
MMA  118.1 117.0 4.60 0.0750 0.250 0.250–250 <LOD <LOD 0.300–13.3 1.00–5.60
EMA  132.1 131.0 3.00 0.0750 0.250 0.250–100 <LOD <LOD 0.300–48.1 3.20–16.5
aKGA  146.1 144.9 11.5 9.00 30.0 30.0–1500 30.2–32.0 <LOD 30.4–107 <LOD
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3.2.4. Precision and accuracy
The back-calculated concentrations of QC samples prepared
in water resulted in acceptable accuracy of 96.4–100.1% withA, l-lactic acid; aHBA, -hydroxybutyric acid; bHBA, -hydroxybutyric acid; pH
thylmalonic acid; aKGA, -ketoglutaric acid; tR , retention time; m/z, target mass; L
lank biological samples) within the retention time windows of the
hromatographic peaks of analytes and IS. This was also veriﬁed
uring the routine analysis. Average retention times and extract
arget mass (m/z) of all analytes in six spiked healthy individuals
lasma/urine are shown in Table 1.
.2.2. Linearity of calibration curves and sensitivity
A linear regression model with 1/x2 weighting resulted in the
est accuracy (93.1–104.0%) and precision (<5.5%) over the entire
alibration range and was considered the most appropriate regres-
ion model for all eight acids. This was expected considering
he heteroscedasticity of data when validating a method over a
road calibration range. The ﬁnal regression model also resulted
n small and evenly distributed residual errors and high coefﬁ-
ient of regression. The accuracy of all eight acids ranged from
2.0–104.0%, 96.0-105.0% and 97.1–104.0% at LLOQ, ULOQ and
ver-curve, respectively. Inter-assay, intra-assay, and total preci-
ion of all eight acids at LLOQ, ULOQ and over-curve were <7.0%,
4.1% and <3.6%, respectively. There were no carry-over effects for
ny analytes or SIL-IS. The LOD, LLOQ and the calibration ranges of
ll eight acids are shown in Table 1.
The calibration curves were prepared in water and additional
alidation procedures were necessary to evaluate the appropriate-
ess of this approach. At QC low, medium and high concentrations,
he RF ranged from 0.93 to 1.04 (RSD < 3.9%) in plasma and from 0.97
o 1.01 (RSD < 1.4%) in urine for all eight acids. The implementation
f RF for QC samples spiked in plasma/urine did not result in bet-
er accuracy or precision; i.e. the absolute sum of relative residuals
as higher when implementing a RF than without the correction
or both plasma and urine samples (data not shown). Thus, a RF was
ot necessary despite using different matrices for calibration curves
nd QC samples compared to clinical samples. Furthermore, ade-
uate accuracy and precision were shown when spiking QC samples
n blank plasma and urine and quantifying them using a calibration
urve prepared in water (supplementary Table 1). This supports
urther the parsimonious approach of not compensating for the
ifferent matrices.
.2.3. Recovery and matrix effects
All analytes showed high process efﬁciency and recovery
ith no substantial matrix effects in six individual healthy
lasma/urine sources: process efﬁciency = 94.6–99.8% (RSD < 2.7%);
ecovery = 94.0–99.8% (RSD < 4.1%) and matrix effects = −3.7 to 3.4%
RSD < 4.2%) (supplementary Table 2). The high recovery and lack of
atrix effect conﬁrmed that the SPE procedure provided an excel-
ent method for extraction of the target analytes in both urine and
lasma samples. Post-column infusions showed that only lactic acidp-hydroxyphenyllactic acid; MA,  malonic acid; MMA,  methylmalonic acid; EMA,
lower limit of quantiﬁcation; LOD, limit of detection.
displayed a clear endogenous peak in the extracted blank plasma
but not in urine, due to higher concentrations in blank plasma from
healthy volunteers compared to the LOD of the assay (Table 1).Fig. 2. Extracted chromatogram of all eight acids spiked in water at QC low level.
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Fig. 3. Extracted chromatogram of acids found in a plasma sample (A) and in a urine sample (B) from a patient with severe malaria. Measured concentrations in (A)
LA  = 1169 g/mL, aHBA = 38.4 g/mL, bHBA = 38.0 g/mL, pHPLA = 4.30 g/mL and aKGA = 32 g/mL. Measured concentrations in (B) LA = 513 g/mL, aHBA = 69.5 g/mL,
b aKGA
i
a
c
3
f
a
f
l
m
l
d
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3
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p
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c
eHBA  = 111 g/mL, pHPLA = 27.7 g/mL, MMA  = 13.3 g/mL, EMA  = 48.1 g/mL and 
ntra-assay, inter-assay and total precisions below 7.6% for
ll samples (supplementary Table 3). Fig. 2 shows extracted
hromatogram of all eight acids spiked in water at QC low level.
.2.5. Stability
All eight acids remained stable in plasma and urine during three
reeze/thaw cycles, at ambient temperature, and also when stored
t 4 ◦C up to 48 h. All acids were also stable at ambient temperature
or at least 4 h before SPE, and at 20 ◦C in the autosampler for at
east 72 h. All acids showed long-term stability in plasma and urine
atrices for at least 1 month, and in stock solution (water) for at
east 4 months. All stability results met  FDA acceptance criteria, the
ifferences between the stored and fresh solution of all eight acids
n plasma and urine were <8.6% with a precision <7.0%.
.3. Clinical applicability
The clinical applicability of our method was demonstrated by
 preliminary analysis of plasma and urine samples collected in
atients with severe malaria from Chittagong, Bangladesh and in
ealthy volunteers (Table 1). The preliminary results showed that
oncentration of ﬁve of the eight potential acids were signiﬁcantly
levated in plasma and seven were elevated in urine samples, = 107 g/mL.
respectively. An extracted chromatogram of a plasma and urine
sample from a representative patient recruited in the study is
shown in Fig. 3. A larger study has been planned to explore and
evaluate in more detail the role of these acids in the pathogenesis
of severe malaria.
4. Conclusions
An accurate and precise simultaneous LC–MS method was
developed and validated for quantitative assessment of eight
potential small organic acids in plasma and urine. This method
will provide an important tool for studying the pathogenesis of
acidosis in patients with severe malaria and other conditions
associated with acidosis. The method was shown to be sensi-
tive, reproducible and suitable for small volumes of plasma or
urine (i.e. 100 L). The method utilized SPE in a 96-well for-
mat, which permits high-throughput processing and automation
of routine analysis of clinical samples. The presented LC–MS
method provides an accurate tool for the identiﬁcation and
quantiﬁcation of as yet unknown acids in patients with severe
malaria. This will enable further the assessment of their pro-
gnostic and pathophysiological signiﬁcance in this devastating
disease.
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